Last reviewed · How we verify
THYROGLOBULIN
At a glance
| Generic name | THYROGLOBULIN |
|---|---|
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
Common side effects
Key clinical trials
- Dysregulation of the Soluble α-Klotho-FGF23 Axis in Hashimoto's Thyroiditis: A Case-Control Study
- Empirical Radioactive Iodine Therapy in DTC (PHASE1,PHASE2)
- Molecular Analysis for Precision Surgery in Thyroid Cancer Trial (NA)
- Novel Antineuronal Antibodies in Gastrointestinal Motility Disorders
- Active Surveillance and Surgery Outcomes in Low Risk Papillary Thyroid Cancer
- Deciding on Active Surveillance or Surgery for Primary Management of Low Risk Papillary Thyroid Cancer
- LOng COvid COmorbidities: Endocrine,Metabolic,Neuropsychiatric,Muscle,Cardiovascular,Pulmonary,Dermatologic Dysfunctions
- Diagnostic Accuracy of Fluorodeoxyglucose-18 PET in the Evaluation of RPTC With Patient's Raised Thyroglobulin Level
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- THYROGLOBULIN CI brief — competitive landscape report
- THYROGLOBULIN updates RSS · CI watch RSS